Eun Yang analyst

Currently out of the existing stock ratings of Eun Yang, 120 are a BUY (79.47%), 26 are a HOLD (17.22%), 5 are a SELL (3.31%).

Eun Yang

Work Performance Price Targets & Ratings Chart

Analyst Eun Yang, carries an average stock price target met ratio of 57.66% that have a potential upside of 35.97% achieved within 323 days. Previously, Eun Yang worked at JEFFERIES.

Eun Yang’s has documented 303 price targets and ratings displayed on 42 stocks. The coverage was on Healthcare, Basic Materials, Technology, Energy sectors.

Most recent stock forecast was given on RIGL, Rigel Pharmaceuticals at 05-Nov-2025.

Wall Street Analyst Eun Yang

Analyst best performing recommendations are on RIGL (RIGEL PHARMACEUTICALS).
The best stock recommendation documented was for RIGL (RIGEL PHARMACEUTICALS) at 6/8/2022. The price target of $10 was fulfilled within 9 days with a profit of $2.99 (42.65%) receiving and performance score of 47.39.

Average potential price target upside

ALBO Albireo Pharma ALXN Alexion Pharmaceuticals AMAG AMAG Pharmaceuticals AMGN Amgen BBIO BridgeBio Pharma BPMC Blueprint Medicines Corp CNTA Centessa Pharmaceuticals PLC ADR FPRX Five Prime Therapeutics LJPC La Jolla Pharmaceutical Co RDUS Schnitzer Steel Industries RIGL Rigel Pharmaceuticals TBIO Telesis Bio UTHR United Therapeutics BMRN Biomarin Pharmaceutical HALO Halozyme Therapeutics ARWR Arrowhead Pharmaceuticals NCNA NuCana PLC LUMO Lumos Pharma ATXS Astria Therapeutics CVAC CureVac NV GBIO Generation Bio Co OPK Opko Health PYXS Pyxis Oncology WVE Wave Life Sciences Ltd TSHA Taysha Gene Therapies  BMEA Biomea Fusion RPHM Reneo Pharmaceuticals AVTE Aerovate Therapeutics RLYB Rallybio Corp DYN Dyne Therapeutics  ALB Albemarle Corp ARRY Array Technologies  AVT Avnet BP BP PLC ADR CV DBVT DBV Technologies DCPH Deciphera Pharmaceuticals LLC DRNA Dicerna Pharmaceuticals ELVN Enliven Therapeutics KROS Keros Therapeutics  NBRV Nabriva Therapeutics AG PRME Prime Medicine, Common Stock

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 15-Feb-2023

$42

$-2.15 (-4.87%)

$42

3 years 5 months 12 days ago
(15-Feb-2023)

0/16 (0%)

$-2.18 (-4.93%)

Hold Since 11-Jan-2023

$42

$-2.15 (-4.87%)

$68

3 years 6 months 16 days ago
(11-Jan-2023)

0/3 (0%)

$-2.1 (-4.76%)

Hold Since 11-Jan-2023

$42

$-2.15 (-4.87%)

$82

3 years 6 months 16 days ago
(11-Jan-2023)

0/4 (0%)

$-2.1 (-4.76%)

Hold Since 11-Jan-2023

$55

3 years 6 months 16 days ago
(11-Jan-2023)

0/1 (0%)

$36.77 (201.70%)

Buy Since 09-Jan-2023

$42

$-2.15 (-4.87%)

$61

3 years 6 months 18 days ago
(09-Jan-2023)

0/2 (0%)

$-1.85 (-4.22%)

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Eun Yang?

On 2008

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?